HTG –
STATUTORY REPORT JUNE 2022
STATUTORY REPORT JUNE 2022
Highlights: • Research and development costs of $1.8M as Nyrada’s lead preclinical programs advance (FY2021: $2.2M). • Robust cash position… Read more
Nyrada : Improving lives through innovation.
Incannex Healthcare (ASX: IHL, NASDAQ: IXHL) announced the appointment of Mr Robert B. Clark to the board of directors of… Read more
On Friday 5th August 2022, Incannex Healthcare Limited (ASX: IHL, NASDAQ: IXHL) announced it had completed the acquisition of APIRx… Read more
Incannex is a global biotech company developing cannabinoid and psychedelic compound medicines. Our mission is to deliver novel drugs and… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical… Read more
Highlights: • Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A • Engagement of Curia follows achievement… Read more
• Global pharmaceutical leader, Dr. Gisela Mautner appointed as Non-Executive Director • Dr. Mautner brings over 20 years of extensive… Read more